William Blair cut shares of Vital Therapies (NASDAQ:VTL) from an outperform rating to a market perform rating in a research note published on Wednesday, September 12th, Marketbeat Ratings reports.
A number of other research firms have also weighed in on VTL. ValuEngine lowered shares of Vital Therapies from a buy rating to a hold rating in a research report on Wednesday, September 12th. BidaskClub downgraded shares of Vital Therapies from a strong-buy rating to a buy rating in a report on Thursday, August 16th. BTIG Research restated a hold rating on shares of Vital Therapies in a report on Monday, May 28th. Finally, Cantor Fitzgerald set a $18.00 price objective on shares of Vital Therapies and gave the stock a buy rating in a report on Sunday, September 9th. Seven research analysts have rated the stock with a hold rating, Vital Therapies currently has a consensus rating of Hold and a consensus target price of $12.00.
Shares of NASDAQ:VTL traded down $0.05 during trading on Wednesday, reaching $0.34. 7,704,187 shares of the company traded hands, compared to its average volume of 1,516,578. Vital Therapies has a 1-year low of $0.23 and a 1-year high of $9.75. The firm has a market capitalization of $11.67 million, a P/E ratio of -0.26 and a beta of 4.29.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.03. Sell-side analysts expect that Vital Therapies will post -1.11 earnings per share for the current year.
In other news, Director Muneer A. Satter sold 11,382,277 shares of the company’s stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $0.36, for a total transaction of $4,097,619.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Muneer A. Satter sold 447,500 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $0.36, for a total transaction of $161,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 11,929,271 shares of company stock worth $4,292,912. 33.90% of the stock is currently owned by insiders.
Several hedge funds have recently made changes to their positions in VTL. Redmile Group LLC acquired a new position in Vital Therapies in the second quarter valued at approximately $7,502,000. TD Asset Management Inc. lifted its holdings in Vital Therapies by 50.2% in the second quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock valued at $249,000 after buying an additional 12,144 shares during the period. Millennium Management LLC lifted its holdings in Vital Therapies by 65.6% in the first quarter. Millennium Management LLC now owns 414,540 shares of the company’s stock valued at $2,819,000 after buying an additional 164,175 shares during the period. Quantitative Systematic Strategies LLC acquired a new position in Vital Therapies in the second quarter valued at approximately $139,000. Finally, Northern Trust Corp lifted its holdings in Vital Therapies by 12.0% in the first quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock valued at $569,000 after buying an additional 8,993 shares during the period. Institutional investors own 32.62% of the company’s stock.
Vital Therapies Company Profile
Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.